Early Primary Tumor Size Reduction Is an Independent Predictor of Improved Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib

BACKGROUND: In metastatic renal cell carcinoma (mRCC) patients treated with targeted agents and their primary tumor (PT) in situ, early PT decrease in size correlates with improved overall PT response, but the effect on overall survival (OS) is unknown. OBJECTIVE: To evaluate whether early PT size r...

Full description

Saved in:
Bibliographic Details
Published in:Eur Urol
Main Authors: Abel, E. Jason, Culp, Stephen H., Tannir, Nizar M., Tamboli, Pheroze, Matin, Surena F., Wood, Christopher G.
Format: Artigo
Language:Inglês
Published: 2011
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4378714/
https://ncbi.nlm.nih.gov/pubmed/21784574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2011.07.008
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items